HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yongchuan Gu Selected Research

PR-104A

1/2018Drug-DNA adducts as biomarkers for metabolic activation of the nitro-aromatic nitrogen mustard prodrug PR-104A.
5/2014The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
3/2014A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
12/2013Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
10/2011A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.
9/2011Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
6/2011Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
3/2011Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
6/2009Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.
9/2007Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yongchuan Gu Research Topics

Disease

21Hypoxia (Hypoxemia)
11/2019 - 07/2007
14Neoplasms (Cancer)
01/2020 - 07/2007
2Neoplasm Metastasis (Metastasis)
11/2015 - 04/2014
2Leukemia
07/2015 - 09/2011
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
07/2015 - 09/2011
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020
1Hypothermia
01/2017
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
07/2015
1Hepatocellular Carcinoma (Hepatoma)
01/2015
1Ovarian Neoplasms (Ovarian Cancer)
04/2014
1Prostatic Neoplasms (Prostate Cancer)
04/2014
1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
03/2014
1Neutropenia
10/2011
1Glioblastoma (Glioblastoma Multiforme)
10/2011
1Sarcoma (Soft Tissue Sarcoma)
10/2011
1Melanoma (Melanoma, Malignant)
10/2011
1Thrombocytopenia (Thrombopenia)
10/2011
1Fever (Fevers)
10/2011
1Infections
10/2011
1Fatigue
10/2011
1Anus Neoplasms (Anal Cancer)
10/2011
1Hypersensitivity (Allergy)
06/2009

Drug/Important Bio-Agent (IBA)

16ProdrugsIBA
11/2019 - 07/2007
11PR-104AIBA
01/2018 - 07/2007
10PR-104IBA
01/2015 - 07/2007
9Oxidoreductases (Dehydrogenase)IBA
11/2019 - 06/2009
6DNA (Deoxyribonucleic Acid)IBA
11/2019 - 07/2007
5Aldo-Keto ReductasesIBA
01/2020 - 03/2011
5Phosphates (Orthophosphate)IBA
01/2018 - 09/2007
5Tirapazamine (SR 4233)IBA
01/2017 - 07/2007
5CEN-209IBA
01/2017 - 12/2013
4Hydroxylamine (Hydroxylamine Hydrochloride)IBA
01/2015 - 07/2007
4Messenger RNA (mRNA)IBA
05/2014 - 06/2011
3AminesIBA
01/2015 - 03/2010
2Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
11/2019 - 01/2018
2Pharmaceutical PreparationsIBA
01/2018 - 01/2018
2azomycinIBA
01/2018 - 04/2014
2NitroimidazolesIBA
01/2018 - 04/2014
24-nitroimidazoleIBA
01/2018 - 04/2014
2TH 302IBA
10/2015 - 05/2014
2Cytotoxins (Cytolysins)IBA
04/2014 - 01/2008
2EstersIBA
06/2011 - 03/2010
2Mechlorethamine (Nitrogen Mustard)FDA Link
03/2010 - 07/2007
2nitromide (Unistat)IBA
03/2010 - 07/2007
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
01/2020
1IC87361IBA
11/2019
1DNA-Activated Protein KinaseIBA
11/2019
1formic acid (formate)IBA
11/2019
1DNA AdductsIBA
01/2018
1OxidesIBA
01/2017
1Antineoplastic Agents (Antineoplastics)IBA
01/2017
1TriazinesIBA
01/2017
1rho Guanine Nucleotide Dissociation Inhibitor betaIBA
11/2015
1Carrier Proteins (Binding Protein)IBA
11/2015
1Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
11/2015
1Biomarkers (Surrogate Marker)IBA
10/2015
1EnzymesIBA
10/2015
1Carbonic Anhydrase IXIBA
07/2015
1pimonidazoleIBA
07/2015
1Sorafenib (BAY 43-9006)FDA Link
01/2015
1SolutionsIBA
11/2014
1Flavin-Adenine Dinucleotide (FAD)IBA
05/2014
1diphenyliodoniumIBA
05/2014
1FlavoproteinsIBA
05/2014
1Cadherins (E-Cadherin)IBA
04/2014
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2014
1dactolisibIBA
04/2014
1SulfonamidesIBA
04/2014
1SN 34037IBA
03/2014
1Oxygen (Dioxygen)IBA
12/2013
1Zinc Finger NucleasesIBA
12/2013
1NADPH-Ferrihemoprotein Reductase (Cytochrome P450 Reductase)IBA
12/2013
1fluoromisonidazoleIBA
10/2012
1Aldo-Keto Reductase Family 1 Member C3IBA
09/2011
1Ethyl MethanesulfonateIBA
06/2011
1DuocarmycinsIBA
03/2011
1Naproxen (Naprosyn)FDA LinkGeneric
03/2011
1Alkylating AgentsIBA
07/2010
1Mitomycin (Mitomycin-C)FDA LinkGeneric
06/2009
1Chlorambucil (Leukeran)FDA Link
06/2009
1Cisplatin (Platino)FDA LinkGeneric
01/2008
1GemcitabineFDA Link
07/2007
1Docetaxel (Taxotere)FDA Link
07/2007

Therapy/Procedure

4Radiotherapy
01/2018 - 07/2007
2Drug Therapy (Chemotherapy)
10/2011 - 07/2007
2Therapeutics
06/2011 - 07/2010
1Intravenous Infusions
10/2011
1Aftercare (After-Treatment)
07/2007